Robert Nelsen - 19 Oct 2022 Form 3/A - Amendment Insider Report for Prime Medicine, Inc. (PRME)

Role: Director, 10%+ Owner
Signature: /s/ Carman Alenson attorney-in-fact
Issuer symbol: PRME
Transactions as of: 19 Oct 2022
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 24 Oct 2022, 16:40:10 UTC
Date Of Original Report: 19 Oct 2022
Previous filing: 06 Oct 2022
Next filing: 26 Oct 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	PRME	Series A Convertible Preferred Stock							19 Oct 2022	Common Stock	16,080		See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") are convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.
F2	Shares held by a trust for the benefit of family members of the Reporting Person that were not included in the initial report.

Content

The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") are convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and will automatically convert into the number of shares shown in Column 3 immediately prior to the closing of the Issuer's initial public offering. The Preferred Stock has no expiration date.

Shares held by a trust for the benefit of family members of the Reporting Person that were not included in the initial report.